Relation between herpes simplex viruses and human immunodeficiency virus infections

Archives of Dermatology

Volumn 135, Issue 11, 1999, Pages 1393-1397

  Severson, Jessica L ^a   Tyring, Stephen K ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; VALACICLOVIR; ZIDOVUDINE;

COMORBIDITY; DISEASE COURSE; DISEASE TRANSMISSION; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROANGIOPATHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE;

EID: 0032705387     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.135.11.1393     Document Type: Review

References (70)

1. Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection: an emerging disease? Infect Dis Clin North Am. 1998;12:47-61.
2. O'Farrell N, Tovey SJ. High cumulative incidence of genital herpes amongst HIV-1 seroposilive heterosexuals in south London. Int J STD AIDS. 1994;5:415-418.
3. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 1995;123: 845-847.
4. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:21-28.
5. Heng MCY, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet. 1994;343:255-258.
6. Reyes M, Graber J, Reeves W. Acyclovir-resistant HSV: preliminary results from a national surveillance system. Paper presented at: International Conference on Emerging Infectious Diseases: March 10, 1998; Atlanta, Ga. Abstract.
7. Barry DW, Lehrman SN, Ellis MM. Clinical and laboratory experience with acyclovir-resistant herpes viruses. J Antimicrob Chemother. 1986;18(suppl B):75-84.
8. McLaren C, Corey L, Dekket C, Barry DW. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. J Infect Dis. 1983; 148:868-875.
9. Lehrman SN, Douglas JM, Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy: relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med. 1986;104:786-790.
10. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir: Acyclovir Study Group. J Infecf Dis. 1994;169:1338-1341.
11. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH Jr. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med. 1990;112:416-422.
12. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother. 1993; 37:357-359.
13. loannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis. 1998;178:349-359.
14. Schacker T, Lu H, Zeh J, Shaughnessy M, Corey L. HSV suppression is associated with a significant decrease in plasma levels of HIV. Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; May 20, 1998; Alexandria, Va. Abstract 260.
15. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337:1105-1111.
16. Hook EW III, Cannon RO, Mahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis. 1992;165:251-255.
17. Boulos R, Ruff AJ, Nahmias A, et al. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human Tlymphotropic virus type 1 infections: the Johns Hopkins University (JHU)/Centre pour le Developpement et la Sante (CDS) HIV Study Group. J Infect Dis. 1992;166:418-420.
18. Ryder RW, Ndilu M, Hassig SE, et al. Heterosexual transmission of HIV-1 among employees and their spouses at two large businesses in Zaire. AIDS. 1990;4: 725-732.
19. Often MW Jr, Zaidi AA, Peterman TA, Rolfs RT, Witte JJ. High rate of HIV sero-conversion among patients attending urban sexually transmitted disease clinics. AIDS. 1994;8:549-553.
20. Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanual JC, Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS. 1989;3: 519-523.
21. European Study Group. Risk factors for male to female transmission of HIV. BMJ. 1989 298:411-415.
22. Clumeck N, Taelman H, Hermans P, Piot P, Schoumacher M, De Wit S. A cluster of HIV infection among heterosexual people without apparent risk factors. N Engl J Med. 1989;321:1460-1462.
23. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet. 1989;2:403-407.
24. Castro KG, Lieb S, Jaffe HW, et al. Transmission of HIV in Belle Glade, Florida: lessons for other communities in the United States. Science. 1988;239:193-197.
25. Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA. 1988;260:1429-1433.
26. Kingsley LA, Armstrong J, Rahman A, Ho M, Rinaldo C Jr. No association between herpes simplex virus type-2 seropositivity or anogenital lesions and HIV seroconversion among homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1990;3:773-779.
27. Hayes CG, Manaloto CR, Basaca-Sevilla V, et al. Epidemiology of HIV infection among prostitutes in the Philippines. J Acquir Immune Defic Syndr Hum Retrovirol. 1990;3:913-920.
28. Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA. 1988;259:1048-1050.
29. VanRaden M, Kaslow R, Kingsley L, et al. The role of ulcerative genital diseases in promoting acquisition of HIV-1 by homosexual men. Programs and abstracts of the Fifth International AIDS Conference; 1989; Montreal, Ontario. Abstract Th.A.0.17.
30. Greenblatt RM, Lukehart SA, Plummer FA, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS. 1988;2:47-50.
31. Keet I, Lee F, van Griensven G, et al. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourinary Med. 1990;66:330-333.
32. Telzak EE, Chiasson MA, Bevier PJ, Stoneburner RL, Castro KG, Jaffe HW. HIV-1 seroconversion in patients with and without genital ulcer disease: a prospective study. Ann Intern Med. 1993;119:1181-1186.
33. Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;29:61-77.
34. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions: an immunohistologic study. J Clin Invest. 1985; 75:226-233.
35. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis. 1994;169:956-961.
36. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998;280:61-66.
37. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-1230.
38. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;86:1082-1089.
39. Rios Z, Bios EO, Garcia MI, et al. Changes in viral expression and cytokine profile induced by a polyantigenic immunomodulator in HIV-infected peripheral blood mononuclear cells. Cell Mol Biol (Noisy-le-grand). 1995;41(suppl 1):S93-S101.
40. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis. 1996;174:1191-1199.
41. Peterman TA, Stoneburner RL, Allen JR. Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections [published correction appears in JAMA. 1989;262:502]. JAMA. 1988;259:55-58.
42. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346:530-536.
43. Hanenberg RS, Rojanapithayakorn W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet. 1994;344:243-245.
44. Nelson KE, Celentano DD, Eiumtrakol S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med. 1996;335: 297-303.
45. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities: The Genital Ulcer Disease Surveillance Group. J Infect Dis. 1998;178:1795-1798.
46. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [published correction appears in Science. 1997;275:14]. Science. 1996;272:1167-1170.
47. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter: AIDS Clinical Trials Group Study 175 Virology Study Team [published erratum appears in N Engl J Med. 1997;337:1097]. N Engl J Med. 1996;335:1091-1098.
48. Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis. 1992;166:494-499.
49. Griffiths PD. Studies to define viral cofactors for human immunodeficiency virus. Infect Agents Dis. 1992;1:237-244.
50. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997;176: 766-770.
51. Kucera LS, Leake E, Iyer N, Raben D, Myrvik QN. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4* cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses. 1990;6: 641-647.
52. Quinnan GV Jr, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA. 1984;252:72-77.
53. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305:1439-1444.
54. Maier JA, Bergman A, Ross MG. Acquired immunodeficiency syndrome manifested by chronic primary genital herpes. Am J Obstet Gynecol. 1986;155:756-758.
55. Corey L, Wald A. Genital herpes. In: Holmes K, ed. Sexually Transmitted Diseases. New York, NY: McGraw Hill Book Co; 1999:285-312.
56. + cell counts in patients with HIV infection. AIDS. 1992;6:1317-1320.
57. Nelson JA, Ghazal P, Wiley CA. Role of opportunistic viral infections in AIDS. AIDS. 1990;4:1-10.
58. Pannuti CS, Cristina M, Finck DS, et al. Asymptomatic perianal shedding of herpes simplex virus in patients with acquired immunodeficiency syndrome. Arch Dermatol. 1997;133:180-183.
59. + lymphocyte count <50/μL. J Infect Dis. 1995;171:829-836.
60. Locke I, Young C, Saltzman R. Famciclovir safety experience in long-term treatment and in immunocompromised patients. Paper presented at: 8th International Congress on Infectious Diseases: May 15, 1998: Boston, Mass. Abstract.
61. Lawrence A, Bell A. Valaciclovir for prevention of recurrent herpes virus infection in HIV-infected individuals: a double-blind controlled trial. Poster presentation at: 8th European Congress of Clinical Microbiology and Infectious Diseases; October 27, 1997; Lausanne, Switzerland.
62. Burnside A, Preston R, Crann R, Young C. Famciclovir for suppression of recurrent genital herpes in HIV-infected patients. Paper presented at: 36th Annual Meeting of the Infectious Diseases Society of America; November 14, 1998; Denver, Colo.
63. Frechette G, Romanowsi B. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. Paper presented at: Sixth Annual Canadian Conference on HIV/AIDS Research; July 16, 1997; Ottawa, Ontario.
64. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore). 1997;76:369-380.
65. Ambinder RF, Burns WH, Lietman PS, Saral R. Prophylaxis: a strategy to minimise antiviral resistance. Lancet. 1984;1:1154-1155.
66. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with the acquired immunodeficiency syndrome. N Engl J Meet. 1989:320:297-300.
67. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989;320:293-296.
68. Morris SA, Kessler HA, Fife KH. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS [letter]. J Infect Dis. 1988; 157:209-210.
69. Youle MM, Hawkins DA, Collins P, et al. Acyclovir-resistant herpes in AIDS treated with foscarnet [letter]. Lancet. 1988:2:341-342.
70. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997;176:892-898.